HAL (France)
open access
Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research
Since the development of the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator in 2012, these therapies have revolutionized patients’ health. They are now the most effective treatment for people with cystic fibrosis (pwCF). In fact, elexacaftor/tezacaftor/ivacaftor and vanza
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation#1103729
- Safety Study of Ivacaftor in Subjects With Cystic Fibrosis#912617
- Adherence patterns and their determinants to CFTR modulators in France#1345667
- Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)#911075
- 28 Day Repeat Dose in Cystic Fibrosis Patients#806235
Record · ID 1329017
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive